Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive declineRik Ossenkoppele, Oskar Hansson, Alexa Pichet Binette et al.|Nature Medicine|2022Cited by 483
Sex, amyloid, and <i>APOE</i> ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well‐characterized cohortsRachel F. Buckley, Elizabeth C. Mormino, Rebecca E. Amariglio et al.|Alzheimer s & Dementia|2018Cited by 289
Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's diseasePratishtha Chatterjee, Ralph N. Martins, Steve Pedrini et al.|Alzheimer s & Dementia|2021Cited by 238
Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive ImpairmentCherie Strikwerda‐Brown, Jens C. Pruessner, Diana A. Hobbs et al.|JAMA Neurology|2022Cited by 133
Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trialsRik Ossenkoppele, Oskar Hansson, Suzanne E. Schindler et al.|Nature Aging|2025Cited by 68